TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
The Oncternal Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. Its focus is on drug development on promising yet untapped biological pathways implicated in cancer progression. The company was founded in 1997 and is headquartered in San Diego, CA.
What was Oncternal Therapeutics’s price range in the past 12 months?
Oncternal Therapeutics lowest stock price was $1.49 and its highest was $10.56 in the past 12 months.
What is Oncternal Therapeutics’s market cap?
Oncternal Therapeutics’s market cap is $217.30M.
What is Oncternal Therapeutics’s price target?
The average price target for Oncternal Therapeutics is $9.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $9.00 ,the lowest forecast is $9.00. The average price target represents 104.55% Increase from the current price of $4.4.
What do analysts say about Oncternal Therapeutics?
Oncternal Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
When is Oncternal Therapeutics’s upcoming earnings report date?
Oncternal Therapeutics’s upcoming earnings report date is Nov 11, 2021 which is next month.
How were Oncternal Therapeutics’s earnings last quarter?
Oncternal Therapeutics released its earnings results on Aug 05, 2021. The company reported -$0.156 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.018.
Is Oncternal Therapeutics overvalued?
According to Wall Street analysts Oncternal Therapeutics’s price is currently Undervalued.
Does Oncternal Therapeutics pay dividends?
Oncternal Therapeutics does not currently pay dividends.
What is Oncternal Therapeutics’s EPS estimate?
Oncternal Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncternal Therapeutics have?
Oncternal Therapeutics has 49,390,000 shares outstanding.
What happened to Oncternal Therapeutics’s price movement after its last earnings report?
Oncternal Therapeutics reported an EPS of -$0.156 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went up 12.533%.
Which hedge fund is a major shareholder of Oncternal Therapeutics?
Currently, no hedge funds are holding shares in ONCT